BRIEF-FDA Announces Six Additional Awardees Under The CNPV Pilot Program
Reuters
Nov 07
BRIEF-FDA Announces Six Additional Awardees Under The CNPV Pilot Program
Nov 6 (Reuters) - FDA:
FDA: SIX ADDITIONAL AWARDEES UNDER THE COMMISSIONER’S NATIONAL PRIORITY VOUCHER (CNPV) PILOT PROGRAM
FDA: ZONGERTINIB FOR HER2 LUNG CANCER, DOSTARLIMAB FOR RECTAL CANCER SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS
FDA: CASGEVY FOR SICKLE CELL DISEASE, ORFORGLIPRON FOR OBESITY AND RELATED HEALTH CONDITIONS SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS
FDA: WEGOVY FOR OBESITY, BEDAQUILINE FOR DRUG-RESISTANT TUBERCULOSIS IN YOUNG CHILDREN SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.